Reforming the FDA

“In many ways, the bill requires the FDA to do things that it is already supposed to do—once more, with feeling,” says Avik Roy. He’s talking about a bill introduced by Sens. Richard Burr (R., N.C.) and Tom Coburn (R., Okla.) Among other things, it would:

  • Retract the dumb 2007 conflict-of-interest rules for FDA advisory committees.
  • Create more accountability for meeting drug-review deadlines.
  • Stop forcing companies to do unnecessary and expensive busywork.
  • Take more advantage of clinical trials in other countries.

More on the “PATIENTS’ FDA Act” in the Forbes.

Comments (4)

Trackback URL | Comments RSS Feed

  1. brian says:

    Sounds good.

    Anything to weaken the FDA.

  2. Devon Herrick says:

    The current system fosters a climate where the FDA is risk averse. Under such a system, patients potentially lack access to therapies that, on balance, would benefit far more people than might be harmed. The appropriate risk/benefit ratio will vary from person to person. The key isn’t reducing all adverse effect to zero. Rather, it’s communicating the potential risks and benefits and allowing doctors and patients decide what is appropriate.

  3. Bruce says:

    Why not abollish the FDA?

  4. brian says:

    Agreed.